Altimmune, Inc. (NASDAQ: ALT) is a Healthcare company (Biotechnology) with a market capitalization of $298M. The Maz Rating grades it against the other companies in its sector.
Altimmune, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.53, Altimmune, Inc. trades at 11376.0x sales and 0.7x book value. Over the last twelve months it generated about $26171 of revenue and a net loss of $141M. It runs a gross margin of -238196.2%, an operating margin of -442580.8% and a net margin of -401361.5%. It shows return on equity of -29.3%, return on invested capital of -23.8% and a free cash flow yield of -34.6%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 23.93. Over the past 52 weeks the share price ranged from $1.50 to $6.44, with a beta of 0.18.
Altimmune, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 12 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.